Provided by Tiger Trade Technology Pte. Ltd.

Tarsus Pharmaceuticals, Inc.

73.16
+0.94001.30%
Post-market: 73.160.00000.00%17:34 EDT
Volume:481.75K
Turnover:35.26M
Market Cap:3.21B
PE:-67.59
High:73.93
Open:72.22
Low:71.20
Close:72.22
52wk High:91.53
52wk Low:53.89
Shares:43.88M
Float Shares:35.64M
Volume Ratio:0.64
T/O Rate:1.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0824
EPS(LYR):-1.5900
ROE:-13.68%
ROA:-5.48%
PB:9.26
PE(LYR):-46.01

Loading ...

Tarsus Advances TP-05 Lyme Prevention Trial, Setting Up a New Mid-Stage Catalyst for TARS Investors

TIPRANKS
·
May 21

Tarsus and John Cena Partner to Raise Awareness of Demodex Blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

THOMSON REUTERS
·
May 14

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

GlobeNewswire
·
May 14

Mizuho Securities Remains a Buy on Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
May 08

Tarsus Pharmaceuticals (TARS) Gets a Buy from Guggenheim

TIPRANKS
·
May 08

Tarsus Pharmaceuticals (TARS) Losses Narrow In Q1 2026 Challenging Bearish Narratives

Simply Wall St.
·
May 08

Tarsus to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 08

Tarsus Pharmaceuticals Earnings Call Signals Durable Growth

TIPRANKS
·
May 07

Tarsus Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Tarsus Q1 FY26 net loss narrows to $7 million; net product sales rise 85% to $145.4 million

Reuters
·
May 07

Tarsus Pharmaceuticals Q1 EPS $(0.16) Beats $(0.33) Estimate, Sales $162.054M Beat $148.422M Estimate

Benzinga Earnings
·
May 07

BRIEF-Tarsus Pharmaceuticals Q1 EPS USD -0.16

Reuters
·
May 07

Tarsus Pharmaceuticals Inc - Reaffirms FY2026 Xdemvy Net Product Sales Guidance of $670 Mln-$700 Mln

THOMSON REUTERS
·
May 07

Tarsus Pharmaceuticals Q1 Revenue USD 145.387 Million VS. Ibes Estimate USD 148.4 Million

THOMSON REUTERS
·
May 07

Tarsus Pharmaceuticals - Reaffirmed Full-Year 2026 Guidance of $670-700 Million of Xdemvy Net Product Sales

THOMSON REUTERS
·
May 07

LifeSci Capital Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
May 06

Tarsus Pharmaceuticals Inc expected to post a loss of 37 cents a share - Earnings Preview

Reuters
·
May 05

Buy Rating Reaffirmed on XDEMVY as Inventory Dynamics Seen as Transient and $88 Price Target Remains Unchanged

TIPRANKS
·
May 04

Tarsus Pharmaceuticals Price Target Maintained With a $88.00/Share by HC Wainwright & Co.

Dow Jones
·
May 04

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

GlobeNewswire
·
Apr 30